Welcome to visit Zhongnan Medical Journal Press Series journal website!
Zhongnan Medical Journal Press Series of Journals Center for Evidence-Based and Translational Medicine of Wuhan University

The title
  • The title
  • The keywords
  • The author
Submit中文版

HomeArticlesVol 34,2024 No.5Detail

Analysis of the disease burden of benign prostatic hyperplasia in China, the United States and Germany at 1990 and 2019

Published on Jun. 01, 2024Total Views: 191 timesTotal Downloads: 266 timesDownloadMobile

Author: LU Peiwen 1, 2 ZI Hao 2 QIAN Xinhang 1, 2 MING Daojing 1, 2 FANG Cheng 2 LI Xiaodong 1, 3

Affiliation: 1. Department of Urology, Huaihe Hospital of Henan University, Kaifeng 475000, Henan Province, China 2. Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 3. Department of Urology, The First Affiliated Hospital of Henan University, Kaifeng 475000, Henan Province, China

Keywords: Benign prostatic hyperplasia Disease burden Prevalence rate Incidence rate Years lived with disability

DOI: 10.12173/j.issn.1004-5511.202403012

Reference: Lu PW, Zi H, Qian XH, Ming DJ, Fang C, LI XD. Analysis of the disease burden of benign prostatic hyperplasia in China, the United States and Germany at 1990 and 2019[J]. Yixue Xinzhi Zazhi, 2024, 34(5): 545-553. DOI: 10.12173/j.issn.1004-5511.202403012.[Article in Chinese]

  • Abstract
  • Full-text
  • References
Abstract

Objective  To comparatively analyze the disease burden of benign prostatic hyperplasia (BPH) in China, the United States, and Germany between 1990 and 2019.

Methods The Global Burden of Disease 2019 (GBD 2019) was used to comparatively study the prevalence, incidence, years lived with disability (YLD), and standardized rate in China, the United States and Germany between 1990 and 2019.

Results  Compared with 1990, the number of prevalence cases, incidence cases and YLD in China, the United States and Germany all showed an increasing trend in 2019. The prevalence, incidence and YLD rate of BPH patients of all ages in China continued to increase with age, with the highest BPH incidence occuring in the age group of 75~79 years old. In 2019, the prevalence of BPH and YLD rate in the United States increased with age, and were the highest among the elderly aged 80 and above, while the incidence of BPH was the highest in the age group of 70~74 years old. In 1990 and 2019, the incidence of BPH among people aged from 65 to 69 in Germany was the highest, and the age group with the highest prevalence was 75 to 79 years old. BHP patients in 75-79 age group has the highest YLD in Germany. From 1990 to 2019, YLD showed an increasing trend in all three countries. In 2019, the YLD of BPH in China, the United States and Germany was 406,200, 89,400 and 27,300 person-years respectively.

Conclusion  China, the United States, and Germany bear a heavy disease burden of BPH, with China having a higher BPH disease burden than the United States and Germany, particularly among those over 65 years of age and populations in rural and remote areas. Proactive health guidance should be provided for highrisk groups in the future, along with a greater allocation of medical resources.

Full-text
Please download the PDF version to read the full text: download
References

1. Lee SWH, Chan EMC, Lai YK. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and Meta-analysis[J]. Sci Rep, 2017, 7(1): 7984. DOI: 10.1038/s41598-017-06628-8.

2. Van Den Eeden SK, Shan J, Jacobsen SJ, et al. Evaluating racial/ethnic disparities in lower urinary tract symptoms in men[J]. J Urol, 2012, 187(1): 185-189. DOI: 10.1016/j.juro.2011.09.043.

3. 罗丽莎, 栾航航, 朱聪, 等. 1990-2019年中国、日本与韩国的良性前列腺增生疾病负担比较[J]. 现代泌尿外科杂志, 2023, 28(6): 506-512. [Luo LS, Luan  HH, Zhu  C, et al. Disease burden of benign prostatic hyperplasia in China, Japan and South Korea from 1990 to 2019: a comparative study[J]. Journal of Modern Urology, 2023, 28(6), 506-512] DOI: 10.3969/j.issn.1009-8291.2023.06.010.

4. 王嘉俊, 李欣然, 李一荣, 等. 良性前列腺增生生物学标志物的研究进展[J]. 标记免疫分析与临床, 2023, 30(5): 881-886. [Wang JJ, Li XR, Li YR, et al. Advances of biomarkers for benign prostatic hyperplasia[J]. Labeled Immunoassays and Clinical Medicine, 2023, 30(5): 881-886] DOI: 10.11748/bjmy.issn.1006-1703.2023.05.030.

5. 李志国, 苏刚岭, 余钧雷. 岭南地区慢性前列腺增生症特点及治疗经验[J]. 中国社区医师, 2021, 37(10): 66-67. [Li ZG, Su GL, Yu JL. Characteristics and treatment experience of chronic prostate hyperplasia in Lingnan area[J]. Chinese Community Doctors, 2021, 37(10): 66-67.] DOI: 10.3969/j.issn.1007-614x.2021.10.032.

6. Launer BM, McVary KT, Ricke WA, et al. The rising worldwide impact of benign prostatic hyperplasia[J]. BJU Int, 2021, 127(6): 722-728. DOI: 10.1111/bju.15286.

7. 邓通, 蔡林, 陈征, 等. 1990年与2017年中国前列腺癌疾病负担分析[J]. 医学新知, 2020, 30(4): 252-259. [Deng T, Cai L, Chen Z, et al. Analysis of the disease burden of prostate cancer in China in 1990 and 2017[J]. Yixue Xizhi Zazhi, 2020, 30(4): 252-259.] DOI: 10.12173/j.issn.1004-5511.2020.04.01.

8. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet, 2020, 396(10258): 1223-1249. DOI: 10.1016/S0140-6736(20)30752-2.

9. GBD 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019[J]. Lancet, 2020, 396(10258): 1160-1203. DOI: 10.1016/S0140-6736(20)30977-6.

10. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet, 2020, 396(10258): 1204-1222. DOI: 10.1016/S0140-6736(20)30925-9.

11. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2018, 392(10159): 1789-1858. DOI: 10.1016/S0140-6736(18)32279-7.

12. 顾佳敏, 朱聪, 訾豪, 等. 1990-2019年中国良性前列腺增生疾病负担分析[J]. 解放军医学杂志, 2021, 46(10): 984-988. [Gu JM, Zhu C, Zi H, et al. Analysis of the disease burden of benign prostatic hyperplasia in China from 1990 to 2019[J]. Medical Journal of Chinese People's Liberation Army, 2021, 46(10): 984-988.] DOI: 10.11855/j.issn.0577-7402.2021.10.05.

13. GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2018, 392(10159): 1859-1922. DOI: 10.1016/S0140-6736(18)32335-3.

14. 汪哲, 李娜, 包云丽, 等. 1990—2019年中国归因于吸烟的消化系统疾病负担分析与模型预测[J]. 中国循证医学杂志, 2023, 23(11): 1247-1252. [Wang Z, Li N, Bao LY, et al. Analysis and model prediction of the burden of digestive diseases attributed to smoking in China from 1990 to 2019[J]. Chinese Journal of Evidence-Based Medicine, 2023, 23(11): 1247-1252.] DOI: 10.7507/1672-2531.202305138.

15. Pan JG, Jiang C, Luo R, et al. Association of metabolic syndrome and benign prostatic hyperplasia in Chinese patients of different age decades[J]. Urol Int, 2014, 93(1): 10-16. DOI: 10.1159/000354026.

16. Zhang S, Wang Q, Zhao D, et al. Association of sensory impairment with institutional care willingness among older adults in urban and rural China: an observational study[J]. Innov Aging, 2023, 7(3): igad013. DOI: 10.1093/geroni/igad013.

17. Liu D, Li C, Li Y, et al. Benign prostatic hyperplasia burden comparison between China and United States based on the Global Burden of Disease Study 2019[J]. World J Urol, 2023, 41(12): 3629-3634. DOI: 10.1007/s00345-023-04658-8.

18. Nakagawa T, Cho J, Yeung DY. Successful aging in East Asia: comparison among China, Korea, and Japan[J]. J Gerontol B Psychol Sci Soc Sci, 2021, 76(Suppl 1): S17-S26. DOI: 10.1093/geronb/gbaa042.

19. Lee HW, Kim SA, Nam JW, et al. The study about physical activity for subjects with prevention of benign prostate hyperplasia[J]. Int Neurourol J, 2014, 18(3): 155-162. DOI: 10.5213/inj.2014.18.3.155.

20. Sun J, Li Y, Xiao LF, et al. Flattening the curve after the initial outbreak of coronavirus disease 2019: a data-driven modeling analysis for the omicron pandemic in China[J]. Vaccines(Basel), 2023, 11(5): 1009. DOI: 10.3390/vaccines11051009.

21. Luo LS, Jiang JF, Luan HH, et al. Spatial and temporal patterns of prostate cancer burden and their association with socio-demographic index in Asia, 1990-2019[J]. Prostate, 2022, 82(2): 193-202. DOI: 10.1002/pros.24258.

22. 赵虎, 孙士成, 王必亮, 等. 经尿道前列腺钬激光剜除术与经尿道前列腺等离子电切术治疗良性前列腺增生症疗效比较[J]. 中国临床医生杂志, 2020, 48(2): 202-205. [Zhao H, Sun SC, Wang BL, et al. Comparison of the efficacy of transurethral holmium laser enucleation of the prostate and transurethral plasma electrosurgery of the prostate in the treatment of benign prostatic hyperplasia[J]. Chinese Journal for Clinicians, 2020, 48(2): 202-205.] DOI: 10.3969/j.issn.2095-8552.2020.02.025.

23. 章尹岗, 刘文. 经尿道前列腺等离子电切术与经尿道前列腺电切术对良性前列腺增生患者治疗效果及预后性生活质量观察[J]. 中国性科学, 2019, 28(7): 27-30. [Zhang YG, Liu W. Effect of transurethral plasmakinetic resection of prostate and transurethral resection of prostate on benign prostatic hyperplasia and its influence on the quality of sexual life[J]. Chinese Journal of Human Sexuality, 2019, 28(7): 27-30.] DOI: 10.3969/j.issn.1672-1993.2019.07.005.

24. 唐圣闻, 张曼. 尿培养标本不合格率及影响因素分析[J]. 标记免疫分析与临床, 2020, 27(10): 1785-1788, 1819. [Tang SW, Zhang M. Analysis of unqualified rate and influencing factors of urine culture[J]. Labeled Immunoassays and Clinical Medicine, 2020, 27(10): 1785-1788, 1819.] DOI: 10.11748/bjmy.issn.1006-1703.2020. 10.032.

25. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in america project: benign prostatic hyperplasia[J]. J Urol, 2008, 179(5 Suppl): S75-S80. DOI: 10.1016/j.juro.2008.03.141.

26. Lowe FC, Batista J, Berges R, et al. Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion[J]. Prostate Cancer Prostatic Dis, 2005, 8(3): 206-209. DOI: 10.1038/sj.pcan.4500806.

Popular Papers
© 2022 - 2024 Zhongnan Medical Journal Press of Zhongnan Hospital of Wuhan University|Support: Yufu Technology
About NM | Contact us